Effects of Sirolimus on the plasmatic secretome profile of treated β‐Thalassemia patients
inflammation, β‐Thalassemia
INFLAMMATION
In order to better characterize potential systemic effects of Sirolimus treatment on the immune compartment, components of the secretome present in the plasma samples of Sirolimus‐treated patients were analysed by Bioplex technology, that allows the parallel analysis of 27 secreted proteins (interleukins, chemokines, growth factors).Content of IL‐1β (A), IL‐13 (B), G‐CSF (C), IP‐10 (D) and MCP‐1(MCAF) (E) in plasma samples isolated at Day 0 and after 90 or more days from the beginning of sirolimus intake by treated patients. (A) Together, these data suggest that Sirolimus could systemically restore the cytokine milieu of β‐Thalassemia patients dampening Th2 responses and immune suppression environments without provoking excessive inflammation levels.